Health state values during the first year of drug treatment in early-stage parkinsons disease: A prospective, population-based, cohort study

Drugs and Aging

Volumn 26, Issue 11, 2009, Pages 973-980

  Vossius, Corinna ^a,b   Nilsen, Odd Bjarte ^a,c   Larsen, Jan Petter ^a,d  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b Stokka Teaching Nursing Home   (Norway)

^c UNIVERSITY OF STAVANGER   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PARKINSON DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; PARKINSON DISEASE; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS;

EID: 70350515694     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11318750-000000000-00000     Document Type: Article

References (22)

1. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986 Mar; 5 (1): 1-30
2. Tandberg E, Larsen JP, Nessler EG, et al. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Mov Disord 1995 Sep; 10 (5): 541-549
3. Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London. BMJ 2000 Jul 1; 321 (7252): 21-22
4. Alves G, Wentzel-Larsen T, Aarsland D, et al. Progression of motor impairment and disability in Parkinson disease: A population-based study. Neurology 2005 Nov 8; 65 (9): 1436-1441
5. Aarsland D, Karlsen K. Neuropsychiatric aspects of Parkinson's disease. Curr Psychiatry Rep 1999 Oct; 1 (1): 61-68
6. Hagell P, Nordling S, Reimer J, et al. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 2002 Nov; 17 (6): 1213-1220
7. Vossius C, Nilsen OB, Larsen JP. Parkinson's disease and nursing home placement: The economic impact of the need for care. Eur J Neurol 2009 Feb; 16 (2): 194-200
8. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967 May; 17 (5): 427-442
9. Fahn SER. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, et al., editors. Recent developments in Parkinson's disease. Florham Park (NJ): Macmillan Healthcare Information, 1987: 153-163
10. Dowding CH, Shenton CL, Salek SS. A review of the healthrelated quality of life and economic impact of Parkinson's disease. Drugs Aging 2006; 23 (9): 693-721
11. Alves G, Muller B, Herlofson K, et al. Incidence of Parkinson's disease in Norway: The Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2009 Aug; 80 (8): 851-857
12. Schwab RS, England Jr AC, editors. Projection technique for evaluating surgery in Parkinson's disease. Edinburgh: Livingstone, 1969
13. Brazier J, Roberts J, Deverill M. The estimation of a preference- based measure of health from the SF-36. J Health Econ 2002 Mar; 21 (2): 271-292
14. Brazier J, Usherwood T, Harper R, et al. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998 Nov; 51 (11): 1115-1128
15. Parkin SG, Gregory RP, Scott R, et al. Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: A case series of 115 patients. Mov Disord 2002 Jul; 17 (4): 682-692
16. Walters SJ, Brazier JE.What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003; 1: 4
17. Noyes K, Dick AW, Holloway RG. Pramipexole and levodopa in early Parkinson's disease: Dynamic changes in cost effectiveness. Pharmacoeconomics 2005; 23 (12): 1257-1270
18. Siderowf A, Ravina B, Glick HA. Preference-based qualityof- life in patients with Parkinson's disease. Neurology 2002 Jul 9; 59 (1): 103-108
19. Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004 Sep; 13 (9): 873-884
20. Vossius C,Gjerstad M, Baas H, et al. Drug costs for patients with Parkinson's disease in two different European countries. Acta Neurol Scand 2006 Apr; 113 (4): 228-232
21. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999 Jul; 16 (1): 59-69
22. Martinez-Martin P, Arroyo S, Rojo-Abuin JM, et al. Burden, perceived health status, and mood among caregivers of Parkinson's disease patients. Mov Disord 2008 Sep 15; 23 (12): 1673-1680